Zosurabalpin

Zosurabalpin
Clinical data
Other names	N2.2.2.1,3-anhydro(N2-[(2-([2-(aminomethyl)-4'-carboxy[1,1'-biphenyl]-3-yl]sulfanyl)pyridin-3-yl)methyl]-L-ornithyl-L-lysyl-N-methyl-L-tryptophan
Identifiers
	IUPAC name 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;
CAS Number	2379336-76-0;
PubChem CID	148636827;
UNII	5Y6W5N1U0S;
Chemical and physical data
Formula	C43H50N8O5S
Molar mass	790.98 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1[C@H](C(=O)NCC2=C(C=CC=C2SC3=C(CN[C@H](C(=O)N[C@H](C1=O)CCCCN)CCCN)C=CC=N3)C4=CC=C(C=C4)C(=O)O)CC5=CNC6=CC=CC=C65;
	InChI InChI=1S/C43H50N8O5S/c1-51-37(23-30-25-47-34-12-3-2-10-32(30)34)40(53)49-26-33-31(27-16-18-28(19-17-27)43(55)56)11-6-15-38(33)57-41-29(9-8-22-46-41)24-48-35(14-7-21-45)39(52)50-36(42(51)54)13-4-5-20-44/h2-3,6,8-12,15-19,22,25,35-37,47-48H,4-5,7,13-14,20-21,23-24,26,44-45H2,1H3,(H,49,53)(H,50,52)(H,55,56)/t35-,36-,37-/m0/s1; Key:NJFUXFYUHIHHOJ-FSEITFBQSA-N;

Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter.^[1] It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate.^[2] The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.^[3]^[4]^[5]

References

^ Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, et al. (January 2024). "A novel antibiotic class targeting the lipopolysaccharide transporter". Nature. 625 (7995): 566–571. doi:10.1038/s41586-023-06873-0. PMC 10794144. PMID 38172634.
^ Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, et al. (January 2024). "A new antibiotic traps lipopolysaccharide in its intermembrane transporter". Nature. 625 (7995): 572–577. doi:10.1038/s41586-023-06799-7. PMC 10794137. PMID 38172635.
^ US 20190321440A1, Bleicher K, Cheang D, Di Giorgio P, Hu T, Jenny C, Mattei P, Schmitz P, Stoll T, "Peptide macrocycles against acinetobacter baumannii.", issued 21 November 2023, assigned to Hoffmann La Roche Inc.
^ Erbetti I, Ferrari L, Ortombina A, Savoia P, Felici A, Bissantz C, Zampaloni C (December 2023). "2109. In vitro and in vivo Killing Kinetics of Zosurabalpin (RG6006) Against Acinetobacter baumannii.". Open Forum Infectious Diseases. Vol. 10. Oxford University Press. doi:10.1093/ofid/ofad500.1733.
^ Theuretzbacher U (October 2023). "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection. doi:10.1016/j.cmi.2023.09.024. PMID 37805036. S2CID 263722286.

[pmid38172634-1] Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, et al. (January 2024). "A novel antibiotic class targeting the lipopolysaccharide transporter". Nature. 625 (7995): 566–571. doi:10.1038/s41586-023-06873-0. PMC 10794144. PMID 38172634.

[2] Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, et al. (January 2024). "A new antibiotic traps lipopolysaccharide in its intermembrane transporter". Nature. 625 (7995): 572–577. doi:10.1038/s41586-023-06799-7. PMC 10794137. PMID 38172635.

[3] US 20190321440A1, Bleicher K, Cheang D, Di Giorgio P, Hu T, Jenny C, Mattei P, Schmitz P, Stoll T, "Peptide macrocycles against acinetobacter baumannii.", issued 21 November 2023, assigned to Hoffmann La Roche Inc.

[4] Erbetti I, Ferrari L, Ortombina A, Savoia P, Felici A, Bissantz C, Zampaloni C (December 2023). "2109. In vitro and in vivo Killing Kinetics of Zosurabalpin (RG6006) Against Acinetobacter baumannii.". Open Forum Infectious Diseases. Vol. 10. Oxford University Press. doi:10.1093/ofid/ofad500.1733.

[pmid37805036-5] Theuretzbacher U (October 2023). "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection. doi:10.1016/j.cmi.2023.09.024. PMID 37805036. S2CID 263722286.

[1]

[2]

[3]

[4]

[5]

See also

References